Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | NT-112 |
Synonyms | |
Therapy Description |
Limited information is currently available on NT-112, a putative T-cell receptor (TCR) therapy targeting KRAS G12D (Feb 2024). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
NT-112 | NT112|NT 112 | Limited information is currently available on NT-112, a putative T-cell receptor (TCR) therapy targeting KRAS G12D (Feb 2024). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06218914 | Phase I | NT-112 | A Study of NT-112 in HLA-C*08:02-Positive Adult Subjects With Unresectable, Advanced, and/ or Metastatic Solid Tumors Positive for the KRAS G12D Mutation | Recruiting | USA | 0 |